Bilateral Nonsynchronous Male Breast Cancer: Two Case Reports.
SUMMARY: BACKGROUND: Bilateral male breast cancer (MBC) is relatively rare. CASE REPORTS: We report 2 bilateral nonsynchronous MBC cases. Second cancers developed during endocrine therapy with selective estrogen receptor modulators (SERM) after the initial surgeries. Since their second surgeries, both patients continued treatment with another SERM, because their second cancers were also hormone receptor-positive. We discuss the endocrine therapy in men based on a review of the literature. CONCLUSIONS: Adequate treatments for early MBC are still controversial. Aromatase inhibitors (AI) are not as effective in men as in women. We consider the higher androgen levels in men to be a major reason for AI not being as effective as expected, i.e. the hormonal environment is very different from that in women. Thus, different approaches are needed for MBC. With further investigation, it is hoped that methods of achieving maximal AI efficacy for MBC will be established.
Horimoto
Yoshiya
Y
Department of Breast Surgical Oncology, Juntendo University School of Medicine, Tokyo, Japan.
Hino
Mako
M
Saito
Mitsue
M
Arakawa
Atsushi
A
Matsumoto
Toshiharu
T
Kasumi
Fujio
F
Int J Cancer. 1990 Apr 15;45(4):661-5
2323842
J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):293-8
9365204
Am J Clin Oncol. 2002 Jun;25(3):235-7
12040279
Nihon Geka Gakkai Zasshi. 1985 Mar;86(3):266-79
2984536
J Clin Endocrinol Metab. 1996 Aug;81(8):3063-7
8768875
Lancet. 2006 Feb 18;367(9510):595-604
16488803
J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7
10902781
Cancer Treat Rev. 2006 Apr;32(2):101-5
16472925